Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -102.40 | -83.57 | -48.18 | -258.12 | -245.91 |
| Net Profit | -0.46 | 8.42 | -18.69 | -220.23 | -221.11 |
| EPS | -0.46 | 97.25 | 99.82 | 25.98 | 14.81 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| 2,122.16 | 2,122.16 | -- | -- | 2,122.16 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -980.89 | -757.96 | -- | 396.00 | -3,230.05 |
| Return on Capital
| 2,041.15 | 1,088.48 | -- | 7,007.77 | -775.69 |
| Return on Assets
| -260.62 | -220.28 | -124.42 | -301.11 | -391.41 |
| Debt to Equity (x)
| -- | -- | -0.18 | -1.10 | -0.85 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
7,007.77
|
-775.69
|
-108.63
|
-95.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
396.00
|
-3,230.05
|
-108.63
|
-96.98
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-124.42
Lower than Peers by 93.44
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
-124.42
|
-301.11
|
-391.41
|
-89.35
|
-73.60
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
--
|
2,122.16
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
--
|
2,132.66
|
--
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
1.00
|
--
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-48.18
Lower than Peers by 47.38
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
-48.18
|
25.88
|
-227.29
|
-110.48
|
-14.14
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-18.69
Lower than Peers by 11.39
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
-18.69
|
27.68
|
-244.68
|
-112.56
|
23.10
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
99.82
Higher than Peers by 85.17
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
99.82
|
1.00
|
-0.48
|
-27.34
|
0.47
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
78.04
Higher than Peers by 88.22
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
78.04
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.18
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
-0.18
|
-1.10
|
-0.85
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.18
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
-0.18
|
-0.21
|
-0.20
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.26
Lower than Peers by 5.55
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
0.26
|
0.25
|
0.23
|
4.62
|
7.15
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
0.26
Lower than Peers by 5.44
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
0.26
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-43.12
Lower than Peers by 41.03
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
-43.12
|
-81.28
|
-120.70
|
-965.55
|
-296.82
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
--
|
-2.99
|
--
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
--
|
-0.18
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
--
|
-41.25
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
91.17
|
17.91
|
21.78
|
36.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
-0.11
|
0.00
|
0.00
|
-0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
3.22
Lower than Peers by 1.96
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
3.22
|
-0.61
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.22
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
-0.22
|
-0.21
|
-0.16
|
1.12
|
1.82
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
0
Lower than Peers by 146
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Panbela Therapeutics (PBLA)
|
0
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|